CRISPR Therapeutics has transitioned from a commercial-stage launch to a development-stage model, with TTM revenue collapsing to $3.5M (a 90% YoY decline) and gross margins deeply negative at -6,537% TTM, indicating that CASGEVY's initial revenue has faded while fixed manufacturing costs persist.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue collapsed to $10.2M in 2026Q2 (a 90% YoY decline from the $35M peak in 2024Q4), with gross margin at -3.4% and operating margin at -11.3%, reflecting fixed manufacturing costs far ahead of commercial sales.
Q2 2026 CASGEVY revenue acceleration above $5M confirms strong commercial uptake and growth potential.
Upcoming H2 2026 cardiovascular data for CTX310 could validate the multi-platform thesis and trigger a significant stock re-rating.
ARK Investment Management increased its stake, reflecting growing confidence from large investors in CRISPR's pipeline.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 2, 2026 | -$1.15-10.6% vs -$1.04 | $13M-14.1% vs $15M |
Q3 2026 Aug 3, 2026 | -$0.94+21.0% vs -$1.19 | $10M+36.7% vs $7M |
Q2 2026 May 4, 2026 | -$1.28-7.6% vs -$1.19 | $1M-76.0% vs $6M |
Q1 2026 Feb 12, 2026 | -$1.37-19.1% vs -$1.15 | $864,000-81.7% vs $5M |
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
ZUG, Switzerland and BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data in patients with relapsed or refractory large B-cell lymphoma from the ongoing Phase 1/2 trial of zugocabtagene geleucel (zugo-cel), its investigational allogeneic CRISPR/Cas9 gene-edited chimeric antigen receptor (CAR) T cell therapy targeting CD19, will be presented in an oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 12 to 15, 2026.
CRISPR Therapeutics reports higher-than-expected Q3 sales as Casgevy sales surge, while expanding pediatric approvals and advancing multiple clinical programs.
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.15 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to a loss of $1.17 per share a year ago.
Benchmark CRSP against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for CRISPR Therapeutics AG (CRSP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $50.07 | $4.83B | -10.62 | -89.97% | -1812.07% | -25.59% | — | |
| $2.57 | $394.4M | -4.15 | 25.39% | -157.32% | -196.63% | — | |
| $11.35 | $1.27B | -3.73 | 16.92% | -805.75% | -64.73% | — | |
| $26.41 | $2.72B | -25.82 | 120.01% | -73.04% | -9.69% | — | |
| $4.65 | $839.87M | -4.39 | 55.28% | -4613.11% | -188.27% | — | |
| $547.09 | $138.85B | 35.12 | 9.57% | 30.61% | 20.08% | — |
CRISPR Therapeutics AG (CRSP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
CRISPR Therapeutics AG (CRSP) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 3, 2026·SEC
Jun 4, 2026·SEC
May 4, 2026·SEC
Get notified when CRSP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CRISPR Therapeutics AG (CRSP) stock FAQ — growth, dividends, profitability & financials explained
CRISPR Therapeutics AG (CRSP) reported $25.2M in revenue over the trailing twelve months. Revenue was $3.5M in fiscal year 2025.
CRISPR Therapeutics AG (CRSP) revenue fell by 33.1% over the trailing twelve months, compared with the twelve months before.
No. CRISPR Therapeutics AG (CRSP) reported a net loss of $456.1M over the trailing twelve months.
CRISPR Therapeutics AG (CRSP) had a return on equity (ROE) of -25.6% over the trailing twelve months. A negative ROE means the company lost money over the period.
CRISPR Therapeutics AG (CRSP) had negative free cash flow of $379.2M over the trailing twelve months.
